Recap: Biohaven Pharma Q1 Earnings

 

Shares of Biohaven Pharma Hldgs BHVN fell 1.1% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share fell 24.27% over the past year to ($2.97), which missed the estimate of ($2.82).

Revenue of $43,823,000 rose by 3707.38% from the same period last year, which beat the estimate of $40,630,000.

Guidance

Biohaven Pharma Hldgs hasn't issued any earnings guidance for the time being.

Biohaven Pharma Hldgs hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 10, 2021

Time: 08:30 AM

ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1447043&tp_key=ee2b58316f

Technicals

Company's 52-week high was at $100.77

52-week low: $42.74

Price action over last quarter: down 14.37%

Company Overview

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!